Literature DB >> 18521089

Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior.

C L Raison1, A S Borisov, B J Woolwine, Breanne Massung, G Vogt, A H Miller.   

Abstract

Interferon (IFN)-alpha has been used to investigate pathways by which innate immune cytokines influence the brain and behavior. Accordingly, the impact of IFN-alpha on diurnal secretion of hypothalamic-pituitary-adrenal (HPA) axis hormones was assessed in 33 patients eligible for treatment with IFN-alpha plus ribavirin for hepatitis C. In addition, the relationship between IFN-alpha-induced HPA axis changes and proinflammatory cytokines and behavior was examined. Plasma ACTH and cortisol as well as tumor necrosis factor (TNF)-alpha, interleukin-6 and their soluble receptors, were measured hourly between 0900 and 2100 hours at baseline and following approximately 12 weeks of either no treatment (n=13) or treatment with IFN-alpha/ribavirin (n=20). Plasma IFN-alpha was also measured at each visit. Depression and fatigue were assessed using the Montgomery-Asberg depression rating scale and the multidimensional fatigue inventory. Compared to no treatment, IFN-alpha/ribavirin administration was associated with significant flattening of the diurnal ACTH and cortisol slope and increased evening plasma ACTH and cortisol concentrations. Flattening of the cortisol slope and increases in evening cortisol were correlated with increases in depression (r=0.38, P<0.05 and r=0.36, P<0.05, respectively) and fatigue (r=0.43, P<0.05 and r=0.49, P<0.01, respectively). No relationship was found between immune and HPA axis measures, although increases in plasma IFN-alpha, TNF-alpha and soluble TNF-alpha receptor2 were independently correlated with behavioral endpoints. These data indicate that chronic exposure to innate immune cytokines may contribute to the altered diurnal HPA axis activity and behavior found in medically ill individuals. However, given the lack of correlation between HPA axis and immune measures, the mechanism by which chronic cytokine exposure influences HPA axis function remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18521089      PMCID: PMC3403676          DOI: 10.1038/mp.2008.58

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  72 in total

1.  Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response.

Authors:  C Maddock; S Landau; K Barry; P Maulayah; M Hotopf; A J Cleare; S Norris; C M Pariante
Journal:  Mol Psychiatry       Date:  2005-04       Impact factor: 15.992

2.  Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation.

Authors:  Michael R Irwin; Minge Wang; Capella O Campomayor; Alicia Collado-Hidalgo; Steve Cole
Journal:  Arch Intern Med       Date:  2006-09-18

Review 3.  Immune-neuro-endocrine interactions: facts and hypotheses.

Authors:  H O Besedovsky; A del Rey
Journal:  Endocr Rev       Date:  1996-02       Impact factor: 19.871

4.  Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man.

Authors:  H Müller; E Hammes; C Hiemke; G Hess
Journal:  Neuroendocrinology       Date:  1991-11       Impact factor: 4.914

5.  Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

Authors:  Lucile Capuron; Jane F Gumnick; Dominique L Musselman; David H Lawson; Andrea Reemsnyder; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2002-05       Impact factor: 7.853

6.  State and trait affect as predictors of salivary cortisol in healthy adults.

Authors:  Deborah E Polk; Sheldon Cohen; William J Doyle; David P Skoner; Clemens Kirschbaum
Journal:  Psychoneuroendocrinology       Date:  2005-04       Impact factor: 4.905

7.  Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.

Authors:  Lucile Capuron; Charles L Raison; Dominique L Musselman; David H Lawson; Charles B Nemeroff; Andrew H Miller
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

8.  Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration.

Authors:  H Shimizu; K Ohtani; N Sato; T Nagamine; M Mori
Journal:  Endocr J       Date:  1995-08       Impact factor: 2.349

9.  The pattern of hormonal circadian time structure (acrophase) as an assessor of breast-cancer risk.

Authors:  A Ticher; E Haus; I G Ron; L Sackett-Lundeen; I E Ashkenazi
Journal:  Int J Cancer       Date:  1996-03-01       Impact factor: 7.396

10.  Pattern of soluble TNF receptors I and II in sepsis.

Authors:  J Schröder; F Stüber; H Gallati; F U Schade; B Kremer
Journal:  Infection       Date:  1995 May-Jun       Impact factor: 3.553

View more
  82 in total

1.  Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol.

Authors:  Charles L Raison; David B Rye; Bobbi J Woolwine; Gerald J Vogt; Breanne M Bautista; James R Spivey; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2010-05-26       Impact factor: 13.382

2.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

3.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

Review 4.  Immune system to brain signaling: neuropsychopharmacological implications.

Authors:  Lucile Capuron; Andrew H Miller
Journal:  Pharmacol Ther       Date:  2011-02-17       Impact factor: 12.310

5.  Norepinephrine-enhancing antidepressant exposure associated with reduced antiviral effect of interferon alpha on hepatitis C.

Authors:  Renata Fialho; Alison Burridge; Marco Pereira; Majella Keller; Alexandra File; Jeremy Tibble; Richard Whale
Journal:  Psychopharmacology (Berl)       Date:  2015-05-15       Impact factor: 4.530

6.  Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations.

Authors:  Jennifer C Felger; Li Li; Paul J Marvar; Bobbi J Woolwine; David G Harrison; Charles L Raison; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2012-10-13       Impact factor: 7.217

Review 7.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

Review 8.  Cytokines and glucocorticoid receptor signaling. Relevance to major depression.

Authors:  Thaddeus W W Pace; Andrew H Miller
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

9.  Preliminary evidence of an association between an interleukin 6 promoter polymorphism and self-reported attentional function in oncology patients and their family caregivers.

Authors:  John D Merriman; Bradley E Aouizerat; Dale J Langford; Bruce A Cooper; Christina R Baggott; Janine K Cataldo; Anand Dhruva; Laura Dunn; Claudia West; Steven M Paul; Christine S Ritchie; Patrick S Swift; Christine Miaskowski
Journal:  Biol Res Nurs       Date:  2013-03-11       Impact factor: 2.522

10.  CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.

Authors:  C L Raison; R Dantzer; K W Kelley; M A Lawson; B J Woolwine; G Vogt; J R Spivey; K Saito; A H Miller
Journal:  Mol Psychiatry       Date:  2009-11-17       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.